[<SUP>18</SUP>F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease

Simple item page
dc.contributor.authorJuri, Carlos
dc.contributor.authorKramer, Vasko
dc.contributor.authorRiss, Patrick J.
dc.contributor.authorSoza-Ried, Cristian
dc.contributor.authorHaeger, Arlette
dc.contributor.authorPruzzo, Rossana
dc.contributor.authorRosch, Frank
dc.contributor.authorAmaral, Horacio
dc.contributor.authorChana-Cuevas, Pedro
dc.date.accessioned2025-01-20T23:53:35Z
dc.date.available2025-01-20T23:53:35Z
dc.date.issued2021
dc.description.abstractIntroduction
dc.description.abstractDegeneration of dopaminergic, nigrostriatal neurons is the hallmark of Parkinson disease (PD), and PET quantification of dopamine transporters is a widely accepted method for differential diagnosis between idiopathic PD and essential tremor. [F-18]PR04.MZ is a new PET tracer with excellent imaging properties allowing for precise quantification of striatal and extrastriatal dopamine transporter. Here we describe our initial experience with [F-18]PR04.MZ PET/CT in a larger cohort of healthy controls and PD patients as a proof-of-concept study for this tracer. Methods
dc.description.abstractEighteen healthy subjects, 19 early PD patients (Hoehn-Yahr I-II), and 13 moderate-advanced PD patients (Hoehn-Yahr III-IV) underwent static PET/CT scans 60 to 90 minutes after injection of 5.16 +/- 1.03 mCi (191 +/- 38 MBq) [F-18]PR04.MZ. Specific binding ratios (SBRs) were calculated for caudate nucleus, anterior putamen, posterior putamen, substantia nigra (SNpc), compared between different groups and correlated with clinical ratings. Results
dc.description.abstract[F-18]PR04.MZ showed very high and specific uptake in the putamen, caudate, and substantia nigra pars compacta and very low nonspecific binding in other brain regions, and SBR values for the control group were 22.3 +/- 4.1, 19.1 +/- 3.5, and 5.4 +/- 1.2, respectively. A reduction of SBR values was observed in all regions and in both initial and moderate PD, ranging from 35% to 89% (P < 0.001). The observed pattern of reduction was posterior putamen > anterior putamen > substantia nigra pars compacta > caudate, with contralateral posterior putamen being the most affected region. Rostrocaudal depletion gradient was evident in all PD patients and progression correlated with motor manifestations. Conclusions
dc.description.abstract[F-18]PR04.MZ PET/CT is a highly sensitive imaging modality for the detection of dopaminergic deficit in nigrostriatal pathways in PD.
dc.fuente.origenWOS
dc.identifier.doi10.1097/RLU.0000000000003430
dc.identifier.eissn1536-0229
dc.identifier.issn0363-9762
dc.identifier.urihttps://doi.org/10.1097/RLU.0000000000003430
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94977
dc.identifier.wosidWOS:000616255100022
dc.issue.numero2
dc.language.isoen
dc.pagina.final124
dc.pagina.inicio119
dc.revistaClinical nuclear medicine
dc.rightsacceso restringido
dc.subject[F-18]PR04
dc.subjectMZ
dc.subjectdopamine transporter
dc.subjectmovement disorders
dc.subjectParkinson disease
dc.subjectPET imaging
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.title[<SUP>18</SUP>F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease
dc.typeartículo
dc.volumen46
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas